IL211888A - PREPARATIONS FOR PREPARING PHARMACEUTRITOLYL-4-ARM (PEG-1-METILLAN-2-OXO-VINYLAMINO ACETATE-IRINOTTKAN) -20 K FOR PREGNANT PHARMACEUTICAL CONCENTRATION FOR PATIENT - Google Patents
PREPARATIONS FOR PREPARING PHARMACEUTRITOLYL-4-ARM (PEG-1-METILLAN-2-OXO-VINYLAMINO ACETATE-IRINOTTKAN) -20 K FOR PREGNANT PHARMACEUTICAL CONCENTRATION FOR PATIENTInfo
- Publication number
- IL211888A IL211888A IL211888A IL21188811A IL211888A IL 211888 A IL211888 A IL 211888A IL 211888 A IL211888 A IL 211888A IL 21188811 A IL21188811 A IL 21188811A IL 211888 A IL211888 A IL 211888A
- Authority
- IL
- Israel
- Prior art keywords
- pentaerythritolyl
- irinotecan
- prodrug
- oxo
- peg
- Prior art date
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title 1
- 229960004768 irinotecan Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
- 229940126585 therapeutic drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9951608P | 2008-09-23 | 2008-09-23 | |
| US10693108P | 2008-10-20 | 2008-10-20 | |
| US17343309P | 2009-04-28 | 2009-04-28 | |
| PCT/US2009/005284 WO2010036335A1 (en) | 2008-09-23 | 2009-09-23 | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL211888A0 IL211888A0 (en) | 2011-06-30 |
| IL211888A true IL211888A (en) | 2015-08-31 |
Family
ID=41268391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL211888A IL211888A (en) | 2008-09-23 | 2011-03-23 | PREPARATIONS FOR PREPARING PHARMACEUTRITOLYL-4-ARM (PEG-1-METILLAN-2-OXO-VINYLAMINO ACETATE-IRINOTTKAN) -20 K FOR PREGNANT PHARMACEUTICAL CONCENTRATION FOR PATIENT |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8906353B2 (enExample) |
| EP (1) | EP2349346B1 (enExample) |
| JP (3) | JP2012503602A (enExample) |
| KR (1) | KR20110063457A (enExample) |
| CN (1) | CN102164617A (enExample) |
| AU (1) | AU2009297091B2 (enExample) |
| CA (1) | CA2736939C (enExample) |
| CY (1) | CY1122208T1 (enExample) |
| DK (1) | DK2349346T3 (enExample) |
| ES (1) | ES2744975T3 (enExample) |
| HR (1) | HRP20192120T1 (enExample) |
| HU (1) | HUE047352T2 (enExample) |
| IL (1) | IL211888A (enExample) |
| LT (1) | LT2349346T (enExample) |
| MX (1) | MX2011003063A (enExample) |
| PL (1) | PL2349346T3 (enExample) |
| PT (1) | PT2349346T (enExample) |
| RS (1) | RS59607B1 (enExample) |
| SI (1) | SI2349346T1 (enExample) |
| SM (1) | SMT201900609T1 (enExample) |
| WO (1) | WO2010036335A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011003063A (es) | 2008-09-23 | 2011-04-21 | Nektar Therapeutics | Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo. |
| US9359376B2 (en) * | 2011-04-08 | 2016-06-07 | Sphaera Pharma Pte. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
| CN104813167B (zh) * | 2012-11-28 | 2019-04-09 | 尼克塔治疗公司 | 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 |
| EP3258913A1 (en) * | 2015-02-17 | 2017-12-27 | Mallinckrodt Nuclear Medicine LLC | Modified docetaxel liposome formulations and uses thereof |
| AU2017273495B2 (en) | 2016-06-02 | 2023-01-12 | Innopharmax, Inc. | Metronomic oral gemcitabine for cancer therapy |
| CN106539557A (zh) * | 2016-10-08 | 2017-03-29 | 西安交通大学 | 一种基于恒速静脉输入的药代动力学参数的测定方法 |
| EP3852793B1 (en) | 2018-09-17 | 2025-11-19 | The Children's Hospital Of Philadelphia | Macromolecular prodrug peg-[sn22]4 |
| AU2022226605A1 (en) * | 2021-02-23 | 2023-10-12 | Edison Oncology | Compositions and methods to improve the therapeutic benefit of suboptimally administered compounds and therapies for the treatment of diseases |
| CN115317486B (zh) * | 2022-08-17 | 2024-04-19 | 南昌大学 | 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4406793A (en) | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| IL117684A (en) | 1995-04-07 | 2002-02-10 | Pharmacia & Upjohn Inc | Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| PL189698B1 (pl) | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
| US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
| US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| JP2002542304A (ja) | 1999-04-28 | 2002-12-10 | ベクトレイムド インコーポレイテッド | 酵素的に活性化された重合薬物接合体 |
| AU4564200A (en) | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| CA2394980C (en) | 1999-12-22 | 2008-05-13 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| WO2001062299A2 (en) | 2000-02-28 | 2001-08-30 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
| US6629995B1 (en) | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
| DK1301810T3 (da) | 2000-07-21 | 2009-01-26 | Schlumberger Services Petrol | Kernemagnetiske resonansfremgangsmåder til at uddrage information om et fluidum i en klippe |
| US20020182172A1 (en) | 2000-11-30 | 2002-12-05 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US7401013B2 (en) | 2001-10-15 | 2008-07-15 | Lockheed Martin Corporation | Method to optimize test data |
| KR20050040832A (ko) | 2001-10-29 | 2005-05-03 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 단백질 키나아제 ｃ 억제제의 중합체 공액 |
| DE60219677T2 (de) | 2001-10-30 | 2008-05-15 | Nektar Therapeutics Al, Corp., Huntsville | Wasserlösliche polymerkonjugate von retinoesäure |
| AU2002346686A1 (en) * | 2001-12-07 | 2003-06-23 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
| US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
| JP2005529938A (ja) | 2002-06-06 | 2005-10-06 | ユニバーシティ オブ ワシントン | 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| KR20140070676A (ko) | 2002-09-06 | 2014-06-10 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
| CN1852740B (zh) | 2003-09-17 | 2011-05-11 | 耐科塔医药公司 | 多支链聚合物的药物前体 |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| EP1989212B1 (en) | 2006-02-17 | 2013-06-19 | Cascade Prodrug Inc. | Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs |
| MX2009008549A (es) | 2007-02-09 | 2009-08-18 | Enzon Pharmaceuticals Inc | Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina. |
| CN101199857B (zh) | 2007-12-12 | 2011-04-13 | 中国药科大学 | mPEG-PLA-喜树碱类药物的结合物 |
| MX2011003063A (es) | 2008-09-23 | 2011-04-21 | Nektar Therapeutics | Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo. |
-
2009
- 2009-09-23 MX MX2011003063A patent/MX2011003063A/es active IP Right Grant
- 2009-09-23 PT PT97893648T patent/PT2349346T/pt unknown
- 2009-09-23 KR KR1020117005982A patent/KR20110063457A/ko not_active Ceased
- 2009-09-23 JP JP2011527834A patent/JP2012503602A/ja not_active Withdrawn
- 2009-09-23 SI SI200932010T patent/SI2349346T1/sl unknown
- 2009-09-23 DK DK09789364.8T patent/DK2349346T3/da active
- 2009-09-23 AU AU2009297091A patent/AU2009297091B2/en active Active
- 2009-09-23 US US13/120,551 patent/US8906353B2/en active Active
- 2009-09-23 CA CA2736939A patent/CA2736939C/en active Active
- 2009-09-23 HR HRP20192120TT patent/HRP20192120T1/hr unknown
- 2009-09-23 EP EP09789364.8A patent/EP2349346B1/en active Active
- 2009-09-23 RS RS20191501A patent/RS59607B1/sr unknown
- 2009-09-23 HU HUE09789364A patent/HUE047352T2/hu unknown
- 2009-09-23 WO PCT/US2009/005284 patent/WO2010036335A1/en not_active Ceased
- 2009-09-23 SM SM20190609T patent/SMT201900609T1/it unknown
- 2009-09-23 CN CN2009801371326A patent/CN102164617A/zh active Pending
- 2009-09-23 ES ES09789364T patent/ES2744975T3/es active Active
- 2009-09-23 LT LTEP09789364.8T patent/LT2349346T/lt unknown
- 2009-09-23 PL PL09789364T patent/PL2349346T3/pl unknown
-
2011
- 2011-03-23 IL IL211888A patent/IL211888A/en active IP Right Grant
-
2014
- 2014-11-17 JP JP2014232556A patent/JP6076317B2/ja active Active
- 2014-11-26 US US14/555,440 patent/US9801873B2/en active Active
-
2016
- 2016-09-26 JP JP2016186670A patent/JP2016216510A/ja not_active Withdrawn
-
2017
- 2017-10-03 US US15/723,981 patent/US10525051B2/en active Active
-
2019
- 2019-09-17 CY CY20191100970T patent/CY1122208T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015034180A (ja) | 2015-02-19 |
| SMT201900609T1 (it) | 2020-01-14 |
| IL211888A0 (en) | 2011-06-30 |
| CY1122208T1 (el) | 2020-11-25 |
| MX2011003063A (es) | 2011-04-21 |
| PL2349346T3 (pl) | 2020-03-31 |
| US20150087668A1 (en) | 2015-03-26 |
| CA2736939C (en) | 2021-09-14 |
| SI2349346T1 (sl) | 2019-12-31 |
| US20180028525A1 (en) | 2018-02-01 |
| AU2009297091B2 (en) | 2015-03-05 |
| KR20110063457A (ko) | 2011-06-10 |
| AU2009297091A1 (en) | 2010-04-01 |
| JP2012503602A (ja) | 2012-02-09 |
| PT2349346T (pt) | 2019-10-24 |
| JP2016216510A (ja) | 2016-12-22 |
| CA2736939A1 (en) | 2010-04-01 |
| DK2349346T3 (da) | 2019-10-07 |
| JP6076317B2 (ja) | 2017-02-08 |
| US8906353B2 (en) | 2014-12-09 |
| EP2349346B1 (en) | 2019-08-28 |
| US9801873B2 (en) | 2017-10-31 |
| HRP20192120T1 (hr) | 2020-02-21 |
| US20110269789A1 (en) | 2011-11-03 |
| LT2349346T (lt) | 2019-09-25 |
| CN102164617A (zh) | 2011-08-24 |
| RS59607B1 (sr) | 2020-01-31 |
| US10525051B2 (en) | 2020-01-07 |
| EP2349346A1 (en) | 2011-08-03 |
| HUE047352T2 (hu) | 2020-04-28 |
| WO2010036335A1 (en) | 2010-04-01 |
| ES2744975T3 (es) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1800043I1 (hu) | 514 számú gyógyszerkészítmény | |
| IL211028A0 (en) | Linaclotide-containing formulations for oral administration | |
| GB2450753B (en) | New Pharmaceutical formulation | |
| ZA201100615B (en) | Appetising medicament for oral administration in solid form | |
| EP2190853A4 (en) | HALOGENIDE-FREE COMPLEXES FROM GLUCOSAMINE AND AN ACIDIC ACID | |
| IL192565A0 (en) | Medicament for topical use | |
| ZA201005994B (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| EP2010162A4 (en) | COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT | |
| PL2121025T3 (pl) | Sposoby i kompozycje dla dostarczania czynnika terapeutycznego | |
| IL211888A0 (en) | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject | |
| ZA200908962B (en) | A liquid formulation for administering nicotine | |
| ZA200807486B (en) | Medicament formulations comprising fluoroquinolones | |
| ZA201107019B (en) | Menthol-derivative compounds and use thereof as oral and systemic active agents | |
| EP2335697A4 (en) | STABLE PHARMACEUTICAL FORMULATION WITH LIMITED STAINING | |
| EP2275092A4 (en) | PHARMACEUTICAL TAX FORMULATION | |
| IL212603A0 (en) | Combined drug administration | |
| GB0606415D0 (en) | Topical drug delivery | |
| EP2309856A4 (en) | PHARMACEUTICAL COMPOUNDS AS CYTOTOXICA AND ITS APPLICATION | |
| EP2363132A4 (en) | USE OF SOPHORICOSIDE IN DRUG MANUFACTURE | |
| EP2343076A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| GB0918912D0 (en) | Improved medicament formulation | |
| GB0705030D0 (en) | Pharmaceutical formulation | |
| HK1140415A (en) | A liquid formulation for administering nicotine | |
| GB0805292D0 (en) | Pharmaceutical formulation | |
| GB0810217D0 (en) | Pharmaceutical formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB20 | Patent renewed for 20 years |